Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 10

Showing 10 citing articles:

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Identifying and managing adverse prognosis biomarkers among advanced luminal breast cancer patients: what have we learned?
Paul Cottu
European Journal of Cancer (2025), pp. 115228-115228
Closed Access
Mapping Breast Cancer Therapy with Circulating Tumor Cells: the expert perspective
Lorenzo Gerratana, Caterina Gianni, Eleonora Nicolò, et al.
The Breast (2025), pp. 104463-104463
Open Access
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 9
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features
Hélène Salaün, Lounes Djerroudi, Laura Haik, et al.
The Journal of Pathology Clinical Research (2024) Vol. 10, Iss. 3
Open Access | Times Cited: 1
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
Brenno Pastò, Riccardo Vida, Arianna Dri, et al.
The Breast (2024) Vol. 79, pp. 103859-103859
Closed Access | Times Cited: 1
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
Lorenzo Foffano, Linda Cucciniello, Eleonora Nicolò, et al.
The Breast (2024) Vol. 79, pp. 103863-103863
Open Access | Times Cited: 1
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
Lis Victória Ravani, Pedro Calomeni, Maysa Vilbert, et al.
JCO Oncology Practice (2024)
Closed Access
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
Seda Kahraman, Mutlu Hızal, Burçin Çakan Demirel, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Page 1

Scroll to top